PMID- 21872631 OWN - NLM STAT- MEDLINE DCOM- 20120123 LR - 20211020 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 29 IP - 45 DP - 2011 Oct 19 TI - Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: persistence, dampening, and extinction of associations found after a first dose. PG - 7982-91 LID - 10.1016/j.vaccine.2011.08.060 [doi] AB - Previously we found human leukocyte antigen (HLA) associations with humoral immunity following a single dose of measles-containing vaccine. In this study, we sought to determine if HLA associations exist with humoral and cellular immunity following a second dose of measles-containing vaccine and if the associations we found with humoral immunity after the first dose persist following a second dose. We recruited a population-based sample of 346 schoolchildren, all who previously received two doses of a measles-containing vaccine. Molecular HLA classes I and II typing as well as humoral and cellular immune assays (measles-specific IgG antibody levels and lymphoproliferative response) were performed in these subjects. We found significant associations with class I HLA-B (p=0.05) as well as class II HLA-DPB1 (p=0.01) and -DPA1 (p=0.03) genes for measles vaccine-induced antibody levels after the second dose. Similarly, we found significant associations with class II HLA-DQB1 (p=0.05) and -DRB1 (p=0.01) genes for measles-specific lymphoproliferation after the second dose. While we found HLA associations after the second dose that we previously found after the first dose of measles containing vaccine, fewer alleles had statistically significant associations, suggesting that the second dose had a dampening or extinguishing effect on the HLA associations. It appears that the second dose overcomes HLA restriction through an as yet unknown mechanism. Future studies of HLA associations should consider both the effect of dose and the role that subsequent doses might play on genetic associations found with the response to a first dose. CI - Copyright (c) 2011 Elsevier Ltd. All rights reserved. FAU - Jacobson, Robert M AU - Jacobson RM AD - Mayo Clinic, 200 First St SW, Rochester, MN 55905-0001, USA. jacobson.robert@mayo.edu FAU - Ovsyannikova, Inna G AU - Ovsyannikova IG FAU - Vierkant, Robert A AU - Vierkant RA FAU - Pankratz, V Shane AU - Pankratz VS FAU - Poland, Gregory A AU - Poland GA LA - eng GR - R01 AG034676/AG/NIA NIH HHS/United States GR - UL1 RR024150/RR/NCRR NIH HHS/United States GR - R01 AR030582/AR/NIAMS NIH HHS/United States GR - R01 AR030582-34/AR/NIAMS NIH HHS/United States GR - UL1 RR024150-01/RR/NCRR NIH HHS/United States GR - AI-33144/AI/NIAID NIH HHS/United States GR - R01 AR30582/AR/NIAMS NIH HHS/United States GR - R01 AI033144/AI/NIAID NIH HHS/United States GR - R01 AI033144-18/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20110826 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Viral) RN - 0 (HLA Antigens) RN - 0 (Immunoglobulin G) RN - 0 (Measles Vaccine) SB - IM MH - Adolescent MH - Antibodies, Viral/*blood MH - Cell Proliferation MH - Child MH - Female MH - Gene Frequency MH - HLA Antigens/*genetics MH - Humans MH - Immunization, Secondary/*methods MH - Immunoglobulin G/blood MH - Leukocytes, Mononuclear/*immunology MH - Male MH - Measles Vaccine/administration & dosage/*immunology MH - Vaccination/methods PMC - PMC3319093 MID - NIHMS362942 EDAT- 2011/08/30 06:00 MHDA- 2012/01/24 06:00 PMCR- 2012/10/19 CRDT- 2011/08/30 06:00 PHST- 2011/03/21 00:00 [received] PHST- 2011/08/11 00:00 [revised] PHST- 2011/08/13 00:00 [accepted] PHST- 2011/08/30 06:00 [entrez] PHST- 2011/08/30 06:00 [pubmed] PHST- 2012/01/24 06:00 [medline] PHST- 2012/10/19 00:00 [pmc-release] AID - S0264-410X(11)01306-5 [pii] AID - 10.1016/j.vaccine.2011.08.060 [doi] PST - ppublish SO - Vaccine. 2011 Oct 19;29(45):7982-91. doi: 10.1016/j.vaccine.2011.08.060. Epub 2011 Aug 26.